RNA, U7 small nuclear 113 pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU7-113P profile across patient tissues and cancer cell-line models. RNU7-113P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNU7-113P is differentially expressed in 3, with the highest sampling consensus in CHOL. Additionally, RNU7-113P RNA expression shows 7,610 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, CHOL, and GBM as cancer lineages where RNU7-113P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU7-113P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU7-113P survival associations across molecular data types. RNU7-113P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU7-113P RNA expression–survival associations across cancer types. High RNU7-113P expression shows unfavorable associations in LIHC, LUSC, STAD, KICH and ACC, but favorable associations in LAML. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNU7-113P RNA expression.
This table summarizes RNU7-113P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for RNU7-113P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU7-113P shows higher tumor expression in CHOL, BLCA and LIHC. The CHOL box plot shows higher RNU7-113P RNA expression in tumor versus normal tissue (log2 FC = +1.110, t-test p < 0.001).
This table shows molecular features associated with RNU7-113P in patient tissues and cancer cell lines. In patient samples, RNU7-113P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
